Tumor	0	5	B-Pathological_formation
angiogenesis	6	18	O
modulates	19	28	O
leukocyte	29	38	B-Cell
-	38	39	O
vessel	39	45	B-Multi-tissue_structure
wall	46	50	I-Multi-tissue_structure
interactions	51	63	O
in	64	66	O
vivo	67	71	O
by	72	74	O
reducing	75	83	O
endothelial	84	95	B-Gene_or_gene_product
adhesion	96	104	I-Gene_or_gene_product
molecule	105	113	I-Gene_or_gene_product
expression	114	124	O
.	124	125	O

The	127	130	O
expression	131	141	O
of	142	144	O
endothelial	145	156	B-Gene_or_gene_product
cell	157	161	I-Gene_or_gene_product
(	162	163	I-Gene_or_gene_product
EC	163	165	I-Gene_or_gene_product
)	165	166	I-Gene_or_gene_product
adhesion	167	175	I-Gene_or_gene_product
molecules	176	185	I-Gene_or_gene_product
involved	186	194	O
in	195	197	O
leukocyte	198	207	B-Cell
-	207	208	O
vessel	208	214	B-Multi-tissue_structure
wall	215	219	I-Multi-tissue_structure
interactions	220	232	O
is	233	235	O
suppressed	236	246	O
in	247	249	O
malignancies	250	262	O
.	262	263	O

In	264	266	O
the	267	270	O
present	271	278	O
study	279	284	O
,	284	285	O
we	286	288	O
investigated	289	301	O
in	302	304	O
vivo	305	309	O
the	310	313	O
regulation	314	324	O
of	325	327	O
leukocyte	328	337	B-Cell
-	337	338	O
vessel	338	344	B-Multi-tissue_structure
wall	345	349	I-Multi-tissue_structure
interactions	350	362	O
by	363	365	O
the	366	369	O
presence	370	378	O
of	379	381	O
a	382	383	O
tumor	384	389	B-Pathological_formation
.	389	390	O

By	391	393	O
means	394	399	O
of	400	402	O
intravital	403	413	O
microscopy	414	424	O
,	424	425	O
tumor	426	431	B-Gene_or_gene_product
necrosis	432	440	I-Gene_or_gene_product
factor	441	447	I-Gene_or_gene_product
alpha	448	453	I-Gene_or_gene_product
-	453	454	O
stimulated	454	464	O
leukocyte	465	474	B-Cell
-	474	475	O
vessel	475	481	B-Multi-tissue_structure
wall	482	486	I-Multi-tissue_structure
interactions	487	499	O
were	500	504	O
studied	505	512	O
in	513	515	O
ear	516	519	B-Tissue
skin	520	524	I-Tissue
microvessels	525	537	I-Tissue
of	538	540	O
nude	541	545	B-Organism
mice	546	550	I-Organism
bearing	551	558	O
small	559	564	O
human	565	570	B-Organism
LS174T	571	577	B-Pathological_formation
colon	578	583	I-Pathological_formation
carcinomas	584	594	I-Pathological_formation
and	595	598	O
in	599	601	O
C57Bl	602	607	B-Organism
/	607	608	I-Organism
6	608	609	I-Organism
mice	610	614	I-Organism
bearing	615	622	O
murine	623	629	B-Organism
B16F10	630	636	B-Pathological_formation
melanomas	637	646	I-Pathological_formation
.	646	647	O

Leukocyte	648	657	B-Cell
-	657	658	O
vessel	658	664	B-Multi-tissue_structure
wall	665	669	I-Multi-tissue_structure
interactions	670	682	O
were	683	687	O
studied	688	695	O
both	696	700	O
within	701	707	O
and	708	711	O
outside	712	719	O
small	720	725	O
tumors	726	732	B-Pathological_formation
growing	733	740	O
in	741	743	O
the	744	747	O
ear	748	751	B-Organ
,	751	752	O
and	753	756	O
in	757	759	O
ear	760	763	B-Tissue
microvessels	764	776	I-Tissue
of	777	779	O
mice	780	784	B-Organism
with	785	789	O
a	790	791	O
large	792	797	O
tumor	798	803	B-Pathological_formation
growing	804	811	O
on	812	814	O
their	815	820	O
flank	821	826	B-Organism_subdivision
.	826	827	O

Tumor	828	833	B-Pathological_formation
-	833	834	O
free	834	838	O
mice	839	843	B-Organism
were	844	848	O
used	849	853	O
as	854	856	O
controls	857	865	O
.	865	866	O

Compared	867	875	O
with	876	880	O
values	881	887	O
measured	888	896	O
at	897	899	O
the	900	903	O
edge	904	908	O
of	909	911	O
the	912	915	O
ear	916	919	B-Organ
and	920	923	O
in	924	926	O
the	927	930	O
contralateral	931	944	O
ear	945	948	B-Organ
,	948	949	O
leukocyte	950	959	B-Cell
adhesion	960	968	O
was	969	972	O
found	973	978	O
to	979	981	O
be	982	984	O
diminished	985	995	O
significantly	996	1009	O
in	1010	1012	O
vessels	1013	1020	B-Tissue
inside	1021	1027	O
the	1028	1031	O
ear	1032	1035	B-Pathological_formation
tumor	1036	1041	I-Pathological_formation
in	1042	1044	O
both	1045	1049	O
mouse	1050	1055	B-Organism
models	1056	1062	O
.	1062	1063	O

This	1064	1068	O
reduction	1069	1078	O
disappeared	1079	1090	O
with	1091	1095	O
increasing	1096	1106	O
distance	1107	1115	O
from	1116	1120	O
the	1121	1124	O
tumor	1125	1130	B-Pathological_formation
.	1130	1131	O

Surprisingly	1132	1144	O
,	1144	1145	O
the	1146	1149	O
level	1150	1155	O
of	1156	1158	O
leukocyte	1159	1168	B-Cell
adhesion	1169	1177	O
in	1178	1180	O
ear	1181	1184	B-Multi-tissue_structure
venules	1185	1192	I-Multi-tissue_structure
of	1193	1195	O
mice	1196	1200	B-Organism
with	1201	1205	O
a	1206	1207	O
large	1208	1213	O
flank	1214	1219	B-Pathological_formation
tumor	1220	1225	I-Pathological_formation
was	1226	1229	O
also	1230	1234	O
reduced	1235	1242	O
significantly	1243	1256	O
.	1256	1257	O

Leukocyte	1258	1267	B-Cell
rolling	1268	1275	O
,	1275	1276	O
i	1277	1278	O
.	1278	1279	O
e	1279	1280	O
.	1280	1281	O
,	1281	1282	O
the	1283	1286	O
step	1287	1291	O
preceding	1292	1301	O
adhesion	1302	1310	O
,	1310	1311	O
was	1312	1315	O
not	1316	1319	O
influenced	1320	1330	O
by	1331	1333	O
the	1334	1337	O
presence	1338	1346	O
of	1347	1349	O
a	1350	1351	O
tumor	1352	1357	B-Pathological_formation
in	1358	1360	O
nude	1361	1365	B-Organism
mice	1366	1370	I-Organism
,	1370	1371	O
but	1372	1375	O
was	1376	1379	O
down	1380	1384	O
-	1384	1385	O
regulated	1385	1394	O
in	1395	1397	O
immune	1398	1404	O
-	1404	1405	O
competent	1405	1414	O
C57Bl	1415	1420	B-Organism
/	1420	1421	I-Organism
6	1421	1422	I-Organism
mice	1423	1427	I-Organism
.	1427	1428	O

Treatment	1429	1438	O
of	1439	1441	O
mice	1442	1446	B-Organism
bearing	1447	1454	O
a	1455	1456	O
small	1457	1462	O
ear	1463	1466	B-Pathological_formation
tumor	1467	1472	I-Pathological_formation
with	1473	1477	O
a	1478	1479	O
humanized	1480	1489	O
antivascular	1490	1502	O
endothelial	1503	1514	B-Gene_or_gene_product
growth	1515	1521	I-Gene_or_gene_product
factor	1522	1528	I-Gene_or_gene_product
antibody	1529	1537	O
prevented	1538	1547	O
the	1548	1551	O
down	1552	1556	O
-	1556	1557	O
regulation	1557	1567	O
of	1568	1570	O
leukocyte	1571	1580	B-Cell
-	1580	1581	O
vessel	1581	1587	B-Multi-tissue_structure
wall	1588	1592	I-Multi-tissue_structure
interactions	1593	1605	O
inside	1606	1612	O
the	1613	1616	O
tumor	1617	1622	B-Multi-tissue_structure
vessels	1623	1630	I-Multi-tissue_structure
compared	1631	1639	O
with	1640	1644	O
the	1645	1648	O
nontreated	1649	1659	O
group	1660	1665	O
.	1665	1666	O

Fluorescence	1667	1679	O
-	1679	1680	O
activated	1680	1689	O
cell	1690	1694	B-Cell
sorter	1695	1701	O
analysis	1702	1710	O
showed	1711	1717	O
that	1718	1722	O
isolated	1723	1731	O
tumor	1732	1737	B-Cell
ECs	1738	1741	I-Cell
have	1742	1746	O
suppressed	1747	1757	O
levels	1758	1764	O
of	1765	1767	O
intercellular	1768	1781	B-Gene_or_gene_product
adhesion	1782	1790	I-Gene_or_gene_product
molecule	1791	1799	I-Gene_or_gene_product
1	1800	1801	I-Gene_or_gene_product
as	1802	1804	O
compared	1805	1813	O
with	1814	1818	O
ECs	1819	1822	B-Cell
from	1823	1827	O
normal	1828	1834	O
mouse	1835	1840	B-Organism
tissues	1841	1848	B-Tissue
.	1848	1849	O

In	1850	1852	O
cultured	1853	1861	O
b	1862	1863	B-Cell
.	1863	1864	I-Cell
END5	1864	1868	I-Cell
cells	1869	1874	I-Cell
the	1875	1878	O
tumor	1879	1884	B-Gene_or_gene_product
necrosis	1885	1893	I-Gene_or_gene_product
factor	1894	1900	I-Gene_or_gene_product
alpha	1901	1906	I-Gene_or_gene_product
-	1906	1907	O
induced	1907	1914	O
up	1915	1917	O
-	1917	1918	O
regulation	1918	1928	O
of	1929	1931	O
intercellular	1932	1945	B-Gene_or_gene_product
adhesion	1946	1954	I-Gene_or_gene_product
molecule	1955	1963	I-Gene_or_gene_product
1	1964	1965	I-Gene_or_gene_product
and	1966	1969	O
vascular	1970	1978	B-Gene_or_gene_product
cell	1979	1983	I-Gene_or_gene_product
adhesion	1984	1992	I-Gene_or_gene_product
molecule	1993	2001	I-Gene_or_gene_product
1	2002	2003	I-Gene_or_gene_product
was	2004	2007	O
reduced	2008	2015	O
in	2016	2018	O
ECs	2019	2022	B-Cell
that	2023	2027	O
were	2028	2032	O
preincubated	2033	2045	O
with	2046	2050	O
basic	2051	2056	B-Gene_or_gene_product
fibroblast	2057	2067	I-Gene_or_gene_product
growth	2068	2074	I-Gene_or_gene_product
factor	2075	2081	I-Gene_or_gene_product
or	2082	2084	O
vascular	2085	2093	B-Gene_or_gene_product
endothelial	2094	2105	I-Gene_or_gene_product
growth	2106	2112	I-Gene_or_gene_product
factor	2113	2119	I-Gene_or_gene_product
.	2119	2120	O

The	2121	2124	O
current	2125	2132	O
results	2133	2140	O
may	2141	2144	O
have	2145	2149	O
an	2150	2152	O
impact	2153	2159	O
on	2160	2162	O
the	2163	2166	O
effectiveness	2167	2180	O
of	2181	2183	O
clinical	2184	2192	O
immunotherapeutic	2193	2210	O
treatment	2211	2220	O
protocols	2221	2230	O
,	2230	2231	O
because	2232	2239	O
immune	2240	2246	B-Cell
effector	2247	2255	I-Cell
cells	2256	2261	I-Cell
may	2262	2265	O
not	2266	2269	O
be	2270	2272	O
able	2273	2277	O
to	2278	2280	O
enter	2281	2286	O
tumor	2287	2292	B-Pathological_formation
tissue	2293	2299	I-Pathological_formation
.	2299	2300	O

